Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) - Net Assets
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) has net assets worth CN¥41.89 Billion CNY (≈ $6.13 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥89.76 Billion ≈ $13.13 Billion USD) and total liabilities (CN¥47.87 Billion ≈ $7.00 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600332 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥41.89 Billion |
| % of Total Assets | 46.67% |
| Annual Growth Rate | 13.14% |
| 5-Year Change | 31.28% |
| 10-Year Change | 132.95% |
| Growth Volatility | 22.09 |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd - Net Assets Trend (1997–2025)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's net assets have evolved over time, based on quarterly financial data. See 600332 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (1997–2025)
The table below shows the annual net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd from 1997 to 2025. For live valuation and market cap data, see Guangzhou Baiyunshan Pharmaceutical Hold (600332) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥41.12 Billion ≈ $6.02 Billion |
+8.88% |
| 2024-12-31 | CN¥37.77 Billion ≈ $5.53 Billion |
+2.98% |
| 2023-12-31 | CN¥36.68 Billion ≈ $5.37 Billion |
+9.04% |
| 2022-12-31 | CN¥33.64 Billion ≈ $4.92 Billion |
+7.38% |
| 2021-12-31 | CN¥31.33 Billion ≈ $4.58 Billion |
+11.07% |
| 2020-12-31 | CN¥28.21 Billion ≈ $4.13 Billion |
+8.53% |
| 2019-12-31 | CN¥25.99 Billion ≈ $3.80 Billion |
+12.30% |
| 2018-12-31 | CN¥23.14 Billion ≈ $3.39 Billion |
+20.15% |
| 2017-12-31 | CN¥19.26 Billion ≈ $2.82 Billion |
+9.12% |
| 2016-12-31 | CN¥17.65 Billion ≈ $2.58 Billion |
+103.29% |
| 2015-12-31 | CN¥8.68 Billion ≈ $1.27 Billion |
+9.11% |
| 2014-12-31 | CN¥7.96 Billion ≈ $1.16 Billion |
+13.34% |
| 2013-12-31 | CN¥7.02 Billion ≈ $1.03 Billion |
+66.23% |
| 2012-12-31 | CN¥4.22 Billion ≈ $618.15 Million |
+8.45% |
| 2011-12-31 | CN¥3.90 Billion ≈ $569.99 Million |
+6.96% |
| 2010-12-31 | CN¥3.64 Billion ≈ $532.87 Million |
+7.05% |
| 2009-12-31 | CN¥3.40 Billion ≈ $497.76 Million |
+5.48% |
| 2008-12-31 | CN¥3.22 Billion ≈ $471.91 Million |
-2.10% |
| 2007-12-31 | CN¥3.29 Billion ≈ $482.05 Million |
+11.51% |
| 2006-12-31 | CN¥2.95 Billion ≈ $432.29 Million |
+5.25% |
| 2005-12-31 | CN¥2.81 Billion ≈ $410.74 Million |
+6.46% |
| 2004-12-31 | CN¥2.64 Billion ≈ $385.80 Million |
+1.55% |
| 2003-12-31 | CN¥2.60 Billion ≈ $379.91 Million |
+7.16% |
| 2002-12-31 | CN¥2.42 Billion ≈ $354.54 Million |
+6.09% |
| 2001-12-31 | CN¥2.28 Billion ≈ $334.18 Million |
+52.42% |
| 2000-12-31 | CN¥1.50 Billion ≈ $219.25 Million |
-0.32% |
| 1999-12-31 | CN¥1.50 Billion ≈ $219.96 Million |
+7.52% |
| 1998-12-31 | CN¥1.40 Billion ≈ $204.58 Million |
+7.72% |
| 1997-12-31 | CN¥1.30 Billion ≈ $189.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2338542730466.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥23.38 Billion | 61.88% |
| Common Stock | CN¥1.63 Billion | 4.30% |
| Other Comprehensive Income | CN¥3.51 Billion | 9.30% |
| Other Components | CN¥9.27 Billion | 24.52% |
| Total Equity | CN¥37.79 Billion | 100.00% |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Competitors by Market Cap
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enova International Inc
NYSE:ENVA
|
$4.46 Billion |
|
Air Canada
TO:AC
|
$4.46 Billion |
|
Cia de Distribucion Integral
MC:LOG
|
$4.47 Billion |
|
UMICORE S.A UNSP.ADR 1/4
F:NVJ
|
$4.47 Billion |
|
Guangdong Kingshine Electronic Tech
SHE:300903
|
$4.46 Billion |
|
Kilroy Realty Corp
NYSE:KRC
|
$4.46 Billion |
|
Grifols S.A.
MC:GRF
|
$4.46 Billion |
|
RadNet Inc
NASDAQ:RDNT
|
$4.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,904,528,000 to 37,788,048,000, a change of 1,883,520,000 (5.2%).
- Net income of 2,983,113,594 contributed positively to equity growth.
- Dividend payments of 1,300,632,759 reduced retained earnings.
- Other comprehensive income increased equity by 106,745,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.98 Billion | +7.89% |
| Dividends Paid | CN¥1.30 Billion | -3.44% |
| Other Comprehensive Income | CN¥106.75 Million | +0.28% |
| Other Changes | CN¥94.29 Million | +0.25% |
| Total Change | CN¥- | 5.25% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.93x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 15.10x to 0.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥1.44 | CN¥21.69 | x |
| 1998-12-31 | CN¥1.55 | CN¥21.69 | x |
| 1999-12-31 | CN¥1.69 | CN¥21.69 | x |
| 2000-12-31 | CN¥1.72 | CN¥21.69 | x |
| 2001-12-31 | CN¥2.68 | CN¥21.69 | x |
| 2002-12-31 | CN¥2.82 | CN¥21.69 | x |
| 2003-12-31 | CN¥3.00 | CN¥21.69 | x |
| 2004-12-31 | CN¥3.01 | CN¥21.69 | x |
| 2005-12-31 | CN¥3.23 | CN¥21.69 | x |
| 2006-12-31 | CN¥3.44 | CN¥21.69 | x |
| 2007-12-31 | CN¥3.77 | CN¥21.69 | x |
| 2008-12-31 | CN¥3.85 | CN¥21.69 | x |
| 2009-12-31 | CN¥4.07 | CN¥21.69 | x |
| 2010-12-31 | CN¥4.36 | CN¥21.69 | x |
| 2011-12-31 | CN¥4.67 | CN¥21.69 | x |
| 2012-12-31 | CN¥3.25 | CN¥21.69 | x |
| 2013-12-31 | CN¥5.35 | CN¥21.69 | x |
| 2014-12-31 | CN¥5.99 | CN¥21.69 | x |
| 2015-12-31 | CN¥6.54 | CN¥21.69 | x |
| 2016-12-31 | CN¥12.36 | CN¥21.69 | x |
| 2017-12-31 | CN¥11.61 | CN¥21.69 | x |
| 2018-12-31 | CN¥13.33 | CN¥21.69 | x |
| 2019-12-31 | CN¥14.88 | CN¥21.69 | x |
| 2020-12-31 | CN¥16.08 | CN¥21.69 | x |
| 2021-12-31 | CN¥17.88 | CN¥21.69 | x |
| 2022-12-31 | CN¥19.72 | CN¥21.69 | x |
| 2023-12-31 | CN¥21.48 | CN¥21.69 | x |
| 2024-12-31 | CN¥22.08 | CN¥21.69 | x |
| 2025-12-31 | CN¥23.24 | CN¥21.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.89%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.85%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 2.24x
- Recent ROE (7.89%) is below the historical average (10.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 9.58% | 3.63% | 1.02x | 2.58x | CN¥-4.88 Million |
| 1998 | 9.83% | 3.66% | 1.13x | 2.38x | CN¥-2.12 Million |
| 1999 | 9.44% | 3.73% | 1.14x | 2.21x | CN¥-7.64 Million |
| 2000 | 10.46% | 3.46% | 1.38x | 2.19x | CN¥6.49 Million |
| 2001 | 6.73% | 2.74% | 1.44x | 1.70x | CN¥-71.16 Million |
| 2002 | 6.93% | 2.67% | 1.42x | 1.82x | CN¥-70.22 Million |
| 2003 | 5.75% | 2.01% | 1.48x | 1.94x | CN¥-103.15 Million |
| 2004 | 2.27% | 0.72% | 1.49x | 2.12x | CN¥-188.73 Million |
| 2005 | 7.04% | 2.04% | 1.77x | 1.94x | CN¥-77.66 Million |
| 2006 | 8.15% | 2.22% | 1.89x | 1.94x | CN¥-51.48 Million |
| 2007 | 10.95% | 2.72% | 1.98x | 2.03x | CN¥29.11 Million |
| 2008 | 5.84% | 5.17% | 0.85x | 1.32x | CN¥-129.99 Million |
| 2009 | 6.39% | 5.44% | 0.92x | 1.28x | CN¥-119.43 Million |
| 2010 | 7.55% | 5.95% | 1.00x | 1.26x | CN¥-86.83 Million |
| 2011 | 7.60% | 5.29% | 1.12x | 1.28x | CN¥-90.63 Million |
| 2012 | 17.80% | 6.04% | 1.93x | 1.52x | CN¥319.38 Million |
| 2013 | 14.35% | 5.57% | 1.44x | 1.79x | CN¥296.87 Million |
| 2014 | 15.43% | 6.35% | 1.32x | 1.84x | CN¥420.21 Million |
| 2015 | 15.39% | 6.80% | 1.21x | 1.88x | CN¥455.27 Million |
| 2016 | 8.69% | 7.53% | 0.77x | 1.49x | CN¥-226.48 Million |
| 2017 | 10.92% | 9.84% | 0.74x | 1.50x | CN¥174.50 Million |
| 2018 | 15.87% | 8.15% | 0.82x | 2.37x | CN¥1.27 Billion |
| 2019 | 13.19% | 4.91% | 1.14x | 2.35x | CN¥770.40 Million |
| 2020 | 11.15% | 4.73% | 1.03x | 2.29x | CN¥300.76 Million |
| 2021 | 12.80% | 5.39% | 1.04x | 2.28x | CN¥813.66 Million |
| 2022 | 12.37% | 5.60% | 0.95x | 2.33x | CN¥760.01 Million |
| 2023 | 11.61% | 5.37% | 0.96x | 2.25x | CN¥563.75 Million |
| 2024 | 7.90% | 3.78% | 0.92x | 2.28x | CN¥-754.96 Million |
| 2025 | 7.89% | 3.85% | 0.92x | 2.24x | CN¥-795.69 Million |
Industry Comparison
This section compares Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $8,033,608,654
- Average return on equity (ROE) among peers: 5.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | CN¥41.89 Billion | 9.58% | 1.14x | $4.46 Billion |
| China National Accord Medicines Corp Ltd (000028) | $364.45 Million | 5.79% | 2.07x | $1.61 Billion |
| Shenzhen Glory Medical Co Ltd (002551) | $1.18 Billion | 3.74% | 0.13x | $368.69 Million |
| Shandong Realcan Pharmaceutical Co Ltd (002589) | $5.75 Billion | -31.83% | 2.19x | $596.71 Million |
| China National Accord Medicines Corp Ltd (200028) | $452.23 Million | 4.55% | 0.19x | $125.15 Million |
| Qingdao Baheal Medical INC. (301015) | $1.50 Billion | 18.20% | 1.70x | $1.57 Billion |
| China Meheco Co Ltd (600056) | $8.88 Billion | 14.78% | 1.38x | $2.00 Billion |
| China National Medicines Corp Ltd (600511) | $725.96 Million | 18.06% | 1.69x | $3.07 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $31.48 Billion | 6.86% | 0.53x | $2.31 Billion |
| Jointown Pharmaceutical Group Co Ltd (600998) | $21.97 Billion | 7.86% | 2.24x | $3.53 Billion |
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more